HUTCHISON CHINA/S ADR (NASDAQ:HCM) has coverage initiated with a Positive rating

Analyst Ratings For HUTCHISON CHINA/S ADR (NASDAQ:HCM)

Story continues below

Today, MED initiated coverage on HUTCHISON CHINA/S ADR (NASDAQ:HCM) with a Positive.

There are 0 sell ratings, 0 hold ratings, 2 buy ratings, 0 strong buy ratings on the stock.

The current consensus rating on HUTCHISON CHINA/S ADR (NASDAQ:HCM) is Buy with a consensus target price of $38.00 per share, a potential 12.39% upside.

Some recent analyst ratings include

  • 7/23/2018-MED initiated coverage with a Positive rating.
  • 11/1/2016-Beaufort Securities Reiterated Rating of Buy.


    About HUTCHISON CHINA/S ADR (NASDAQ:HCM)
    Hutchison China MediTech Limited, a biopharmaceutical company, engages in the research, development, manufacture, and sale of pharmaceuticals and healthcare products primarily in the People's Republic of China and Hong Kong. It operates through Innovation Platform and Commercial Platform segments. The company discovers and develops therapeutics in oncology and autoimmune diseases, as well as provides research and development services; and develops, manufactures, distributes, markets, and sells prescription and over-the-counter pharmaceutical products, and consumer health products under the Baiyunshan and Shang Yao brands. Its clinical drug candidates include Savolitinib, an inhibitor for treating non-small cell lung, colorectal, and gastric cancer, as well as papillary renal cell carcinoma; Fruquintinib, an oral inhibitor for the treatment of colorectal, non-small cell lung, and gastric cancer; Sulfatinib for treating neuroendocrine tumors, and thyroid and biliary tract cancer; and Epitinib for the treatment of non-small cell lung cancer, as well as for patients with glioblastoma. The company also develops Theliatinib epidermal growth factor receptor inhibitor for treating solid tumors, as well as for patients with esophageal cancer; HMPL-523, an oral inhibitor for the treatment of immunology, rheumatoid arthritis, and hematological cancers; HMPL-689, a small molecule inhibitor for the treatment of hematologic cancers, autoimmunity and transplant organ rejection, and other related inflammation diseases; HMPL-453, a small molecule inhibitor for the treatment of solid tumors; and HMPL-004 for the treatment of ulcerative colitis and Crohn's disease. It has strategic alliances with AstraZeneca AB (publ); Eli Lilly and Company; and Nestlé Health Science SA. The company was founded in 2000 and is headquartered in Central, Hong Kong. Hutchison China MediTech Limited is a subsidiary of Hutchison Healthcare Holdings Limited.

    Recent Trading Activity for HUTCHISON CHINA/S ADR (NASDAQ:HCM)
    Shares of HUTCHISON CHINA/S ADR closed the previous trading session at 33,81 +0,97 2,95 % with 34.51 shares trading hands.

    An ad to help with our costs